Episode 93
Impossible d'ajouter des articles
Désolé, nous ne sommes pas en mesure d'ajouter l'article car votre panier est déjà plein.
Veuillez réessayer plus tard
Veuillez réessayer plus tard
Échec de l’élimination de la liste d'envies.
Veuillez réessayer plus tard
Impossible de suivre le podcast
Impossible de ne plus suivre le podcast
Episode 93
-
Lu par :
-
De :
À propos de ce contenu audio
In this episode Dr. Stader and Dr. Bradley summarize and offer key insights for the following Coaches Top 5 picks discussing the potential role of GLP-1 therapies in alcohol and substance use disorders, risk factors associated with long-term opioid prescribing, patient motivation and readiness to taper opioids for chronic pain, national trends in ADHD medication prescribing, and more!
- GLP-1 Therapeutics and Their Emerging Role in Alcohol and Substance Use Disorders: An Endocrinology Primer Published in the Journal of Endocrine Society, October 2025
- A national cohort study of long-term opioid prescription and sociodemographic and health care-related risk factors Published in Communications Medicine, September 2025
- Patient Motivation to Reduce or Discontinue Opioids for Chronic Pain: Self-efficacy, Barriers, and Readiness to Change Published in the Clinical Journal of Pain, January 2024
- Population-Level Trends in Attention-Deficit/Hyperactivity Disorder Medication Prescribing Published in JAMA Network Open, December 2025
- Increased Avoidance Learning in Chronic Opioid Users Published in JAMA Pyschiatry, November 2025
Vous êtes membre Amazon Prime ?
Bénéficiez automatiquement de 2 livres audio offerts.Bonne écoute !
Aucun commentaire pour le moment
